Bead Spheres Help Occlude Hypervascular Tumors
By HospiMedica International staff writers Posted on 01 Jul 2014 |
Innovative bioresorbable miniscule gelatin beads offer a new embolization treatment option when a permanent embolic agent is not desired.
The Gel-Bead embolization spheres are precisely sized gelatin beads that are inserted into the hypervascular tumor using a delivery catheter. The spheres form an artificial clot that is resorbed over time, providing physicians with an alternative to currently used microspheres, polyvinyl alcohol (PVA), particles, and gelatin foam slurries. The spheres eventually undergo complete degradation, beginning at 4 weeks, with some spheres still present at 12 weeks. Studies showed that the majority of treated vessels showed no signs of recanalization at 12 weeks.
The Gel-Beads are supplied in 20 mL syringes, each containing 1 mL of gelatin spheres suspended in 5 mL of saline, and are available in four sizes of sphere diameter (100–300 µm, 300–500 µm, 500–700V, and 700–1,000 µm), each identified by a different colored syringe plunger. The spheres are manufactured using an emulsion system and cross-linked with glutaraldehyde. The Gel-Bead embolization spheres are a product of Vascular Solutions (Minneapolis, MN, USA), and have been approved by the US Food and Drug Administration (FDA).
“We are very pleased to announce the launch of Gel-Bead, our latest offering to leverage our biologics expertise in the field of embolization,” said Howard Root, CEO of Vascular Solutions. “With the launch of Gel-Bead, we offer the additional configuration of uniform spheres designed for smooth embolic delivery and predictable distribution, all at a very economical price. Over time, we plan to continue to add to our embolization products with future versions designed to meet specific therapeutic needs.”
Related Links:
Vascular Solutions
The Gel-Bead embolization spheres are precisely sized gelatin beads that are inserted into the hypervascular tumor using a delivery catheter. The spheres form an artificial clot that is resorbed over time, providing physicians with an alternative to currently used microspheres, polyvinyl alcohol (PVA), particles, and gelatin foam slurries. The spheres eventually undergo complete degradation, beginning at 4 weeks, with some spheres still present at 12 weeks. Studies showed that the majority of treated vessels showed no signs of recanalization at 12 weeks.
The Gel-Beads are supplied in 20 mL syringes, each containing 1 mL of gelatin spheres suspended in 5 mL of saline, and are available in four sizes of sphere diameter (100–300 µm, 300–500 µm, 500–700V, and 700–1,000 µm), each identified by a different colored syringe plunger. The spheres are manufactured using an emulsion system and cross-linked with glutaraldehyde. The Gel-Bead embolization spheres are a product of Vascular Solutions (Minneapolis, MN, USA), and have been approved by the US Food and Drug Administration (FDA).
“We are very pleased to announce the launch of Gel-Bead, our latest offering to leverage our biologics expertise in the field of embolization,” said Howard Root, CEO of Vascular Solutions. “With the launch of Gel-Bead, we offer the additional configuration of uniform spheres designed for smooth embolic delivery and predictable distribution, all at a very economical price. Over time, we plan to continue to add to our embolization products with future versions designed to meet specific therapeutic needs.”
Related Links:
Vascular Solutions
Latest Surgical Techniques News
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery
- Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions
- Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons
- Next-Gen Computer Assisted Vacuum Thrombectomy Technology Rapidly Removes Blood Clots
- Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices